[1] DI ANGELANTONIO E, BHUPATHIRAJU S N, WORMSER D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents[J]. Lancet, 2016, 388(10046): 776-786. doi:  10.1016/S0140-6736(16)30175-1
[2] World Obesity Federation. World Obesity Atlas 2025[Z/OL]. London: World Obesity Federation, 2025, https://data.worldobesity.org/publications/world-obesity-atlas-2025-v7.pdf.
[3] COSKUN T, SLOOP K W, LOGHIN C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept[J]. Mol Metab, 2018, 18: 3-14. doi:  10.1016/j.molmet.2018.09.009
[4] HIGGINS J, THOMAS J, CHANDLER J, et al. Cochrane handbook for systematic reviews of interventions [EB/OL].(2020-09)[2026-01]. https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current.
[5] FRIAS J P, NAUCK M A, VAN J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial[J]. Lancet, 2018, 392(10160): 2180-2193. doi:  10.1016/S0140-6736(18)32260-8
[6] ROSENSTOCK J, WYSHAM C, FRÍAS J P, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes(SURPASS-1): a double-blind, randomised, phase 3 trial[J]. Lancet, 2021, 398(10295): 143-155. doi:  10.1016/S0140-6736(21)01324-6
[7] DAHL D, ONISHI Y, NORWOOD P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial[J]. Jama, 2022, 327(6): 534. doi:  10.1001/jama.2022.0078
[8] JASTREBOFF A M, ARONNE L J, AHMAD N N, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med, 2022, 387(3): 205-216. doi:  10.1056/NEJMoa2206038
[9] GARVEY W T, FRIAS J P, JASTREBOFF A M, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes(SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 402(10402): 613-626. doi:  10.1016/S0140-6736(23)01200-X
[10] WADDEN T A, CHAO A M, MACHINENI S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial[J]. Nat Med, 2023, 29(11): 2909-2918. doi:  10.1038/s41591-023-02597-w
[11] ARONNE L J, SATTAR N, HORN D B, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity(SURMOUNT-4)[J]. Diabetol Und Stoffwechsel, 2024, 19(S 01): S84-S85.
[12] MALHOTRA A, GRUNSTEIN R R, FIETZE I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity[J]. N Engl J Med, 2024, 391(13): 1193-1205. doi:  10.1056/NEJMoa2404881
[13] ZHAO L, CHENG Z F, LU Y B, et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial[J]. Jama, 2024, 332(7): 551-560. doi:  10.1001/jama.2024.9217
[14] JASTREBOFF A M, LE ROUX C W, STEFANSKI A, et al. Tirzepatide for obesity treatment and diabetes prevention[J]. N Engl J Med, 2025, 392(10): 958-971. doi:  10.1056/NEJMoa2410819
[15] KADOWAKI T, KIYOSUE A, SHINGAKI T, et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease(SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Diabetes Endocrinol, 2025, 13(5): 384-396. doi:  10.1016/S2213-8587(24)00377-2
[16] WING R R, LANG W, WADDEN T A, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes[J]. Diabetes Care, 2011, 34(7): 1481-1486. doi:  10.2337/dc10-2415
[17] GARVEY W T, MECHANICK J I, BRETT E M, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity[J]. Endocr Pract, 2016, 22: 1-203. doi:  10.4158/ep161356.esgl
[18] HANSFORD R, BULLER S, TSANG A H, et al. Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism[J]. Cell Metab, 2025, 37(9): 1820-1834. doi:  10.1016/j.cmet.2025.07.009
[19] 何晓东, 李琴, 刘慧敏, 等. 司美格鲁肽周制剂治疗成人超重和肥胖有效性与安全性的系统评价和Meta分析[J]. 中国医院药学杂志, 2022, 42(16): 1709-1715. doi:  10.13286/j.1001-5213.2022.16.15
[20] ARONNE L J, HORN D B, LE ROUX C W, et al. Tirzepatide as compared with semaglutide for the treatment of obesity[J]. N Engl J Med, 2025, 393(1): 26-36. doi:  10.1056/NEJMoa2416394